| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Microbial Metabolite
Acyl-coenzyme A:cholesterol acyltransferase (ACAT). ACAT catalyzes cholesteryl ester formation from cholesterol and fatty acyl-CoA, playing a key role in cellular cholesterol homeostasis. Terpendole I also shows activity against Gram-positive bacteria, but ACAT is its primary defined molecular target. |
|---|---|
| ln Vitro |
Terpendole I inhibits ACAT with an IC50 of 145 uM in cell-free microsomal assays. It displays antimicrobial activity against Bacillus cereus and Bacillus subtilis (MIC 100 ug/mL each), but no activity against S. aureus, P. aeruginosa, or K. pneumoniae. Weak antifungal activity against Candida albicans (MIC 200 ug/mL). Cytotoxic against HeLa cervical cancer cells with IC50 52.6 uM.
|
| ln Vivo |
No specific in vivo activity data has been reported for Terpendole I. Available research focuses on isolation, structural elucidation, and in vitro characterization. Thus, its efficacy, pharmacokinetics, and toxicity in animal models remain uncharacterized.
|
| Enzyme Assay |
ACAT inhibition is evaluated using rat liver microsomes. Incubate Terpendole I (0-388 uM) with microsomal ACAT, radiolabeled oleoyl-CoA (e.g., [1-14C]oleoyl-CoA) in buffer. After 30 min at 37degC, extract cholesteryl esters with organic solvent, separate by TLC, and quantify radioactive cholesteryl [1-14C]oleate by liquid scintillation counting to calculate IC50 (145 uM).
|
| Cell Assay |
For cytotoxicity, seed HeLa cells in DMEM with 10% FBS in 96-well plates (5,000-10,000 cells/well) overnight. Treat with Terpendole I (0.01-100 uM) for 48 h. Add CCK-8 or MTT reagent, incubate 2-4 h, measure OD450 or OD570. Calculate IC50 (reported 52.6 uM). For antimicrobial activity, use broth microdilution in Mueller-Hinton broth (bacteria) or Sabouraud broth (C. albicans), incubate 18-48 h, determine MIC as lowest concentration with no visible growth.
|
| Animal Protocol |
No published animal protocol exists. A hypothetical protocol for efficacy: Use 6-8 week old BALB/c nude mice bearing HeLa xenografts (100-150 mm3). Administer Terpendole I IP at 10-50 mg/kg daily for 14-21 days, formulated in 10% DMSO, 40% PEG300, 5% Tween-80, 45% saline. Monitor tumor volume and body weight. Endpoint: tumor weight, IHC for Ki-67, cleaved caspase-3.
|
| ADME/Pharmacokinetics |
No dedicated PK study reported. Predicted properties: molecular weight 453.57, LogP 4.51-5.22, 4 H-bond donors, 5-6 acceptors. Expected high membrane permeability and low aqueous solubility. Soluble in DMSO, DMF, ethanol, methanol. Stable powder at -20degC. Oral bioavailability unknown; likely low due to high LogP.
|
| Toxicity/Toxicokinetics |
No specific toxicology data published. In vitro cytotoxicity IC50 of 52.6 uM in HeLa cells indicates potential cytotoxicity at higher concentrations. No in vivo MTD or LD50 data. As a research chemical, handle with standard precautions: gloves, lab coat, fume hood. Not for human use. No teratogenicity or mutagenicity data available.
|
| References | |
| Additional Infomation |
Terpenol I is an oxygen-containing organic compound and an organic heterocyclic tricyclic compound. It has been reported that terpenol I was found in the sorbiform whitefly (Albophoma yamanashiensis), and relevant data are available for reference.
Terpendole I is a natural indoloditerpene first reported in 1995 by Ōmura et al. from Albophoma yamanashiensis. It is a biosynthetic intermediate for more complex terpendoles. It serves as a tool for cholesterol metabolism research and as a reference standard. Not a drug candidate; not FDA-approved. Purity ≥95% for research use. Complexity score 865, 9 stereocenters. Strictly for laboratory use only. |
| Molecular Formula |
C27H35NO5
|
|---|---|
| Molecular Weight |
453.57
|
| Exact Mass |
453.251
|
| CAS # |
167612-17-1
|
| PubChem CID |
10026941
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
668.4±55.0 °C at 760 mmHg
|
| Flash Point |
358.0±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.681
|
| LogP |
4.51
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
33
|
| Complexity |
865
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@]12CC[C@H]3[C@@]4([C@@]1(CC[C@@H]5[C@@]2(C6=C(C5)C7=CC=CC=C7N6)C)O)[C@H](O4)[C@@H]([C@H](O3)C(C)(C)O)O
|
| InChi Key |
AKOANWZRKXOJTC-ZWNZASDISA-N
|
| InChi Code |
InChI=1S/C27H35NO5/c1-23(2,30)21-19(29)22-27(33-22)18(32-21)10-11-24(3)25(4)14(9-12-26(24,27)31)13-16-15-7-5-6-8-17(15)28-20(16)25/h5-8,14,18-19,21-22,28-31H,9-13H2,1-4H3/t14-,18-,19+,21-,22+,24+,25+,26-,27-/m0/s1
|
| Chemical Name |
(1S,2R,5S,7S,8R,9R,11S,12S,15S)-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-6,10-dioxa-24-azaheptacyclo[13.10.0.02,12.05,11.09,11.017,25.018,23]pentacosa-17(25),18,20,22-tetraene-8,12-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2047 mL | 11.0237 mL | 22.0473 mL | |
| 5 mM | 0.4409 mL | 2.2047 mL | 4.4095 mL | |
| 10 mM | 0.2205 mL | 1.1024 mL | 2.2047 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
